



Contents available at [ScienceDirect](https://www.sciencedirect.com)

Diabetes Research
and Clinical Practice

journal homepage: www.elsevier.com/locate/diabres



International
Diabetes
Federation



Race/ethnicity and challenges for optimal insulin therapy



Nayla Cristina do Vale Moreira ^a, Antonio Ceriello ^b, Abdul Basit ^c, Naby Balde ^{d,e,f}, V. Mohan ^g, Ritesh Gupta ^h, Anoop Misra ⁱ, Bishwajit Bhowmik ^j, Moon K. Lee ^{f,k}, Hui Zuo ^l, Zumin Shi ^m, Youfa Wang ⁿ, Renan M. Montenegro ^a, Virginia Oliveira Fernandes ^a, Stephen Colagiuri ^{f,o}, Andrew J.M. Boulton ^{f,p}, Akhtar Hussain ^{a,f,j,q,*}

^a Faculty of Medicine, Federal University of Ceará (FAMED-UFC), Fortaleza-Ceará, Brazil

^b IRCCS MultiMedica, Milan, Italy

^c Baquai Medical University, Karachi, Pakistan

^d Endocrinology and Diabetes Department, Donka Conakry University Hospital, Conakry, Guinea

^e Foundation Diabetes and NCD, Conakry, Guinea

^f International Diabetes Federation, IDF, Brussels, Belgium

^g Dr. Mohans Diabetes Specialties Centre, Chennai, India

^h Fortis CDOC Hospital, New Delhi, India

ⁱ Fortis-C-DOC Centre of Excellence for Diabetes, Metabolic Diseases and Endocrinology, Delhi, India

^j Centre for Global Health Research, Diabetic Association of Bangladesh, Dhaka, Bangladesh

^k Division of Endocrinology & Metabolism, Department of Internal Medicine, Uijeongbu Eulji Medical Center, Eulji University School of Medicine, Uijeongbu, Republic of Korea

^l School of Public Health, Medical College of Soochow University, Suzhou, China

^m Human Nutrition Department, College of Health Sciences, QU Health, Qatar University, Doha, Qatar

ⁿ Global Health Institute, School of Public Health, Xi'an Jiaotong University Health Science Center, Xi'an, China

^o Boden Collaboration, Charles Perkins Centre, University of Sydney, Sydney, Australia

^p University of Manchester, UK

^q Faculty of Health Sciences, Nord University, Bodø, Norway

ARTICLE INFO

Article history:

Received 15 April 2021

Accepted 15 April 2021

Available online 20 April 2021

Keywords:

Race

Ethnicity

Diabetes

Insulin sensitivity

Insulin resistance

Insulin therapy

ABSTRACT

Aims: We aimed to review insulin dosing recommendations, insulin regulation and its determinants, glycaemic response to carbohydrates, and the efficacy and safety of insulin therapy in different races/ethnicities.

Methods: We searched for articles in PubMed and Google Scholar databases up to 31 March 2021, with the following keywords: “ethnicity”, “diabetes”, “insulin”, “history of insulin”, “insulin therapy”, “food/rice”, “carbohydrate intake”, “insulin resistance”, “BMI”, “insulin dosing”, “insulin sensitivity”, “insulin response”, “glycaemic index”, “glycaemic response”, “efficacy and safety”, with interposition of the Boolean operator “AND”. In addition, we reviewed the reference lists of the articles found.

Results: The differential effect of race/ethnicity has not yet been considered in current insulin therapy guidelines. Nevertheless, body size and composition, body mass index, fat distribution, diet, storage, and energy expenditure vary significantly across populations. Further, insulin sensitivity, insulin response, and glycaemic response to carbohydrates

* Corresponding author at: Post box 1490, 8049 Bodø, Norway.

E-mail address: hussain.akhtar@nord.no (A. Hussain).

<https://doi.org/10.1016/j.diabres.2021.108823>

0168-8227/© 2021 The Authors. Published by Elsevier B.V.

This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

differ by ethnicity. These disparities may lead to different insulin requirements, adversely impacting the efficacy and safety of insulin therapy among ethnic groups.

Conclusions: Race/ethnicity affects glucose metabolism and insulin regulation. Until now, international guidelines addressing racial/ethnic-specific clinical recommendations are limited. Comprehensive updated insulin therapy guidelines by ethnicity are urgently needed.

© 2021 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

1. Introduction

Diabetes is a major public health challenge of the 21st century. Currently, around 463 million people (20–79 years) live with diabetes, which corresponds to 9.3% of the global population. By 2045, this number is expected to rise to 700 million. Formerly considered “a disease of the wealthy”, approximately 80% of those with diabetes now live in low- and middle-income countries [1]. Although diabetes is common across the world, ethnic disparities have been consistently reported in relation to diabetes prevalence and incidence, pathophysiology, mortality, and acute and long-term complications [1–3].

Several studies on racial differences in diabetes have shown higher prevalence and incidence rates among non-white populations [2,4,5]. Although the exact reasons remain unknown, these disparities likely emanate from multiple factors, including genetic, epigenetic, different pathophysiological patterns, lifestyle, and environment [2]. Worldwide, Hispanic, and Asian populations present a higher prevalence of diabetes than Europeans and Africans both in their native settings and among their diaspora [1,6]. Evidence suggests that the genetic background of Africans and East Asians makes them more and differentially susceptible to diabetes than Caucasians [7]. Diabetes prevalence also differs considerably among Hispanic and non-Hispanic Asian subgroups in the United States [4,6]. In a nationally representative survey of US adults from 2011 to 2016, the prevalence of diabetes was 12.1% for non-Hispanic white (NHW), whereas it was significantly higher for non-Hispanic black (NHB) (20.4%), Hispanic (22.1%), and non-Hispanic Asian adults (19.1%) [2].

The literature shows that non-Caucasians have higher mortality rates and risk of diabetes complications, after adjusting for confounders [8]. Approximately 4.2 million people died of diabetes in 2019, with marked heterogeneity across the globe. According to the International Diabetes Federation (IDF), death rates attributable to diabetes varied from 6.8% in sub-Saharan Africa, to 8.5% in Europe, around 11% in the Western Pacific region, almost 13% in South and Central America, approximately 14% in the North America, Caribbean, and South East Asia regions, and 16.2% in Middle East and North Africa [1]. In the US, NHB are 2.3 times more likely to die from diabetes than NHW, whereas the figures for Native Americans and Hispanics are 1.9 and 1.5x. Furthermore, Native Hawaiians and Filipinos living in Hawaii are 5.7 and 3.0 times more likely to die from diabetes than NHW [9]. Even

in modern societies where diabetes care is available and accessible for great portion of the population, both micro- and macrovascular complications related to diabetes differ significantly among ethnic groups. Although a lower risk of cardiovascular disease (CVD) has been reported for ethnic minorities in the US, several studies suggest that Native Americans, Hispanics and NHB have an increased risk for lower extremity amputations than NHW [10]. Furthermore, Asians in the UK and the Netherlands, as well as Hispanics and blacks in the US have shown a higher risk of nephropathy and end-stage renal disease. Ethnic minorities in the US also seem to present an increased risk of retinopathy, whereas Algerians in France have a higher risk of neuropathy [8].

Differences in responsiveness to medicinal products have been commonly observed across ethnic groups. Although insulin has been applied in the treatment of diabetes for 100 years, scarce evidence exists regarding potential ethnic differences in response to insulin dosing and formulations. It has been reported that West African descendants (including African Americans and native Ghanaians) have higher degrees of insulin resistance than Caucasians [11,12]. Similarly, despite a higher average energy and fat intake, NHW have also shown lower insulin resistance than Hispanics [13]. Those ethnic differences in insulin sensitivity may affect recommendations on treatment type and dosage. Even though in insulin therapy the dose is individually titrated according to patients' needs and lifestyle, the recommended starting dose may vary across ethnic groups. Therefore, we aimed to review insulin dosing recommendations, insulin regulation and its determinants, glycaemic response to carbohydrates, and efficacy and safety of insulin therapy in different races/ethnicities.

2. Methods

A literature review was carried out to search for articles in PubMed and Google Scholar databases up to 31 March 2021. The following keywords were used: “ethnicity”, “diabetes”, “insulin”, “history of insulin”, “insulin therapy”, “food/rice”, “carbohydrate intake”, “insulin resistance”, “BMI”, “insulin dosing”, “insulin sensitivity”, “insulin response”, “glycaemic index”, “glycaemic response”, “efficacy and safety”, with interposition of the Boolean operator “AND”. Further, we retrieved the full text of relevant studies in the reference lists of the searched articles. Only articles in English were considered.

2.1. Brief history of insulin

In 1889, two German researchers, Oskar Minkowski and Joseph von Mering, found that when the pancreas gland was removed from dogs, the animals developed symptoms of diabetes and died soon afterward. This led to the idea that the pancreas was the site where “pancreatic substances” (insulin) were produced. In 1921, inspired by Mering’ and Minkowski’s studies, Paulescu performed a pancreatectomy in a dog, emulsified the pancreatic tissue and injected it into the jugular vein of the animal. He demonstrated that this pancreatic extract had an anti-diabetic effect [14].

In 1922, for the first time in the history of medicine, an insulin extract was administered to a 14-year-old boy in Toronto General Hospital. Nevertheless, this clinical experimentation was a failure. Following further refinements, a second series of injections effectively controlled glycaemia, glycosuria, and ketonuria. This marked the first successful administration of insulin to a type 1 diabetes patient and, ultimately, led to the development of commercially available insulin [15].

Important progress has been made over the last hundred years. The structure of insulin was delineated in 1955. In 1967, proinsulin was discovered and the radioimmunoassay for C-peptide was developed. In 1972, the U100 insulin was introduced to promote better accuracy in administration, and, in 1982, recombinant human insulin became available. In the 1990s, insulin pen delivery devices became available, followed by the discovery of short (1996) and long (2001) acting insulin analogues [14].

2.2. Insulin dosing: Formulae and challenges in different ethnic groups

Given the progressive nature of type 2 diabetes mellitus (T2DM), many patients eventually require and benefit from insulin therapy. According to the American Diabetes Association (ADA) [16], insulin for T2DM may be started to augment therapy with oral agents. Currently, basal insulin alone is a usual regimen applied in clinical practice. Starting doses can be estimated based on body weight (0.1–0.2 units/kg/day) and the degree of hyperglycaemia. Alternatively, ten units of basal insulin once daily can be added, with individualized titration over days to weeks as needed. Some individuals may also require doses of insulin before meals to reach glycaemic targets. Usually, a dose of 4 units or 10% of the amount of basal insulin at the largest meal or the meal with the highest postprandial excursion is applied for initiating therapy. In metabolically stable type 1 diabetes patients or those with T2DM who require replacement therapy, total daily insulin requirements are also estimated by the weight, with doses ranging from 0.4 to 1.0 units/kg/day (0.5 units/kg/day is a typical starting dose, with 50% of the daily dose as basal insulin and 50% as prandial). The longer-acting basal dose regulates overnight, fasting glucose, whereas shorter acting formulations control postprandial glucose levels. Current recommendations for prandial insulin dose are individualized based on carbohydrate intake, premeal glucose levels, and anticipated activity [16]. Nevertheless, specific features of insulin resis-

tance, insulin secretion, and glycaemic response to carbohydrates in different populations have not yet been addressed in the formulae.

Historically, dosing guidelines have been based on clinical experience and retrospective studies of patients. The first formula proposed in 1922 was also weight based and calculated conservatively to prevent hypoglycaemia and preserve the limited amount of insulin available ($\text{Dose (ml)} = \text{body weight} \times \text{insulin sensitivity of dogs} / 2$) [17]. In 1982, based upon clinical experience with human regular insulin, Skyler et al. [18] suggested that the total basal dose (TBD) should be about 40% of the total daily dose (TDD). In 1998, the “rule of 3” was proposed for estimating carbohydrate-to-insulin ratio ($\text{CIR} = [3 \times \text{weight in lb}] / \text{TDD}$) [19]. Current formulae for estimating the correction factor (CF) are based on the suggestion by Davidson et al. [19] of the “1500 rule”, later modified to “1700” ($\text{CF} = 1700 / \text{TDD}$). These three formulae together became the foundation of the Accurate Insulin Management system. Subsequently, Walsh et al. [20], using retrospective pump download information, suggested that the CIR should be calculated from $450 / \text{TDD}$. Since the previous formulae had been based on regular insulin used in pump treatment, Walsh et al. proposed a modification to $\text{CF} = 2000 / \text{TDD}$. Walsh essentially agreed with Davidson that the formula for estimating the CIR should be $\text{CIR} = (2.6 \times \text{weight in lb}) / \text{TDD}$, reflecting the widespread use of rapid-acting insulin analogs (see Table 1 for a detailed description of the parameters used in the formulae) [20].

Currently, a consensus statement from the American Association of Clinical Endocrinologists/American College of Endocrinology [22], recommends the following formulae: $\text{TBD (U)} = 50\% \text{ of TDD}$, $\text{CIR} = 450 / \text{TDD}$, and $\text{CF} = 1700 / \text{TDD}$. Nevertheless, independent studies in Japan and the US using more rigorous designs suggested that traditional formulae overestimated basal insulin requirements and underestimated bolus requirements [23]. Results from the US showed that the TBD should be 40% of the TDD, whereas data from Japan reported a more appropriate TBD of 30% of the TDD. The Japanese diet with higher-carbohydrate and lower-fat proportions than the US diet possibly explains this difference. Further, Japanese studies also found that the CIR exhibited diurnal variability ranging from $300 / \text{TDD}$ at breakfast to $400 / \text{TDD}$ for lunch or dinner [23]. Hypothetical calculation has shown that the currently used formulae for estimating the CIR and CF may lead to underdosing of bolus insulin by as much as 12.8–50% [21].

High-fat, low-carbohydrate intake reduces the ability of basal insulin to suppress hepatic glucose production [24]. Since the American diet has higher-carbohydrate and lower-fat proportions, it could be assumed that the US recommendations for basal dose would be higher than in countries with lower-fat content in their diet. For the Asian Indian diet [25] (consisting of 78% carbohydrates and 13% fat), for instance, the total bolus dose should be much higher than the US diet, but the total basal dose would be less. Therefore, it is possible that the recommended TBD to be 50% of the TDD may be excessive for India, China, and other countries of similar diet composition [21]. The TBD/TDD ratio of < 30% in the Japanese studies supports this contention [23].

Table 1 – Definition of parameters used in insulin dosing formulae [21].

Parameters	Definitions
TDD	The total basal and prandial insulin dosage.
TBD	The fraction of TDD given as basal insulin.
CIR	A number that, when divided into the number of grams of ingested carbohydrates, indicates the units of insulin needed to lower blood glucose to a pre-meal value within 2–4 h.
CF	A number that, when divided into the difference between actual and target blood glucose, yields the number of extra units of insulin needed to lower blood glucose to the target range, within 2–4 h.
CF: correction factor, CIR: carbohydrate-to-insulin ratio, TBD: total basal dose, TDD: total daily dose	
*Patients with greater insulin sensitivity will have higher CFs and CIRs	

The discrepancies between traditional formulae and data from newer studies may be due to the more rigorous design of the latter. International differences in diet composition may also be important to consider when developing insulin dosing recommendations.

2.3. Evolutionary roots of race/ethnic disparities in glucose metabolism and insulin regulation

It has been hypothesized that depending on a population's genetic or evolutionary history, ethnic differences exist in the optimal states of glucose metabolism and insulin regulation. Human blood glucose levels have likely evolved toward their current equilibrium over thousands of years. As a response to genetic or environmental perturbations, the stability of blood glucose regulation has developed through a hyperbolic function of two variables: insulin sensitivity and insulin response [26,27]. Global migration in ancient days placed people in new environments, under different climate conditions, food availability and exposure to pathogens. These changes may have made some adjustments in factors that influence insulin sensitivity and secretion, such as body size and composition, energy expenditure, storage, and heat production. As these factors altered, novel genetic variations or mutations may have pushed some subpopulations to different points of stability [7,27].

Studies have found ethnic differences in the stabilization points of insulin sensitivity and insulin response to maintain the normal blood glucose levels. It has been observed that Africans have significantly lower insulin sensitivity and higher insulin response to glucose than Caucasians and East Asians. In contrast, East Asians present higher insulin sensitivity and lower insulin response than the other two groups [7]. In a meta-analysis of 74 study cohorts, Kodama et al. [7] calculated the hyperbolic relationship between insulin sensitivity and insulin response in three different populations. They used the mean values of the insulin sensitivity index (SI) and acute insulin response to glucose (AIRg) in normal glucose tolerance (NGT) cohorts and stratified distributions by ethnicity. As shown in Fig. 1, Caucasians clustered around the middle of the hyperbola, whereas African and East Asian subpopulations were in unstable extreme points in the curve. In these areas, small changes in one variable are associated with large nonlinear changes in the other variable. Therefore, it may be hypothesized that, in Africans, even a slight increase in insulin resistance in current days could lead to a rapid increase in the amount of insulin secretion necessary to maintain NGT [7]. Interestingly, it has been reported that African Americans have a twofold increased risk of developing T2DM compared with Caucasians [28]. On the other hand, given the observed limited capacity of insulin secretion in East Asians [29], it can also be speculated that even a small decrease in insulin secretion may lead to a rapid decrease in the threshold level of insulin resistance above which T2DM arises. This may possibly contribute to the high prevalence of diabetes in East Asia nowadays [7].

In any population, genetic predisposition, and environmental triggers likely account for the development of T2DM. The "thrifty genotype" hypothesis proposes that individuals with certain genetically driven metabolic features might have




Fig. 1 – Ethnic differences in the relationship between insulin sensitivity and insulin response in normal glucose tolerance (NGT) cohorts. Scatter plot of insulin sensitivity index (SI) vs. acute insulin response to glucose (AIRg) measured in healthy African, Caucasian, and East Asian cohorts. Each circle corresponds to one study cohort. Each circle area is proportional to the cohort sample size. The solid line is the curve calculated in the meta-analysis of Kodama et al. [7] $\ln(\text{AIRg}) = -0.915 \times \ln(\text{SI}) - 2.82$. The dashed line is the curve of Kahn et al. [26] describing healthy Caucasians $\ln(\text{AIRg}) = -1.0 \times \ln(\text{SI}) - 3.80$. Figure by Kodama et al. Non-commercial creative commons license.

been selected for survival. In primeval times, when food availability was insecure, those who were metabolically "thrifty" had better odds of survival. When food was available, metabolic thriftiness ensured efficient storage of energy for use during famine. Nevertheless, with urbanization and immigration, now this genotype predisposes individuals to insulin resistance and diabetes [3,30]. In the early 1990s, Hales and Barker et al. [31] formulated an alternative explanation for the origins of T2DM, metabolic syndrome and CVD. The "thrifty phenotype" hypothesis suggests that poor intrauterine and infant nutrition produce permanent changes in glucose-insulin metabolism, preparing the individual for a life of starvation. Foetal malnutrition would result in insulin resistance and poor development of pancreatic β -cell mass and function. A limited insulin secretion capacity would not be detrimental to those who remained poorly nourished and thin, and, therefore, insulin sensitive. Nevertheless, if followed by overnutrition in childhood and adult life, an adverse foetal environment might lead to diabetes and other chronic diseases [31].

Historical data suggest that South Asians have become increasingly undernourished since the Mesolithic period. These long-term intergenerational influences, especially those adversely affecting maternal and/or early childhood, may have increased their risk to diabetes [32]. Bavdekar et al. [33] reported a significant association between low birth weight and high insulin resistance in 8-year-old Indian children. Other important contributing factors to diabetes susceptibility in this group include urbanization, decreased

physical activity, higher intake of fat and processed food, increased mental stress, and migration to more affluent countries [34].

In recent history, several nations have suffered from famine. At the end of World War II (1944–1945), severe famine affected the western region of the Netherlands. The Dutch Hunger Winter Famine lasted 5 months, hit people of all social classes and was followed by growing prosperity in the post-war period. Moreover, it impacted foetal nutrition and early development, with resulting epigenetic changes that were linked to an increased risk of T2DM decades later [35]. Prenatal exposure to famine was related to impaired glucose tolerance (IGT) in adulthood and this seemed to be mediated by an insulin secretion defect [35,36].

Similar rises in the prevalence of T2DM have also been observed years after famine in Ukraine [37], Cambodia [38] and China [39]. Individuals exposed to the 1932–1933 Ukraine Famine during early gestation were 1.5-fold more likely to develop T2DM as adults than Ukrainians not affected by the famine [37]. After decades of severe food shortages in 1975–1979, T2DM prevalence in Cambodia rose to levels seen in developed nations [38]. Foetal exposure to the Chinese famine (1959–1961) exacerbated the association between obesity and adult risk of incident T2DM, as well as the association between hypertension and CVD [39].

2.4. Glycaemic response to carbohydrates in different ethnic groups

The glycaemic index (GI) represents the ability of a carbohydrate food to raise blood glucose levels [40]. It has been assumed that the glycaemic potential of certain food is independent of metabolic or demographic differences of the consumer. Nevertheless, different glycaemic responses to the same carbohydrate-containing food or glucose load have been reported across populations [41]. Venn et al. [41] observed that Asians present higher glycaemic responses than Caucasians following a common breakfast cereal (63% higher) and a beverage containing 50 g of glucose (29% higher). For an identical carbohydrate load, South Asians exhibit postprandial glucose peaks that are 2–3 times larger than Caucasians [40]. Furthermore, it has been reported that Hispanics have lower glycaemic excursions after evening meals than Caucasians, whereas Asians show greater excursions after breakfast than Caucasians [42]. Thai, Vietnamese, and Chinese lean young adults showed significantly higher postprandial glycaemia than European Caucasians after a bread meal (75 g carbohydrate) [43].

Traditional Asian diets are known to improve postprandial glucose profile at similar calories and even at greater carbohydrate content than Western diets [44]. Further, low GI Asian meals were shown to improve glycaemic response and even to increase fat oxidation [45]. Until the early 1970s, most traditional Asian diets were less milled or polished. Undermilled rice is nutritionally superior (richer in fibre, polyphenols, and vitamin E) than the fully milled white rice. However, during the last decades, hand-pounded rice has been increasingly replaced with white rice in many Asian countries. A recent study of 132,373 participants has shown that higher con-

sumption of white rice is associated with an increased risk of incident diabetes in South Asia [46]. Ethnic differences have been observed in glycaemic responses to several varieties of rice. Kataoka et al. [47] reported that Chinese people had 60% greater glycaemic responses for five rice varieties than Europeans. Additionally, the GI for four rice varieties was approximately 20% greater in the Chinese [47].

Ethnicity is therefore an important factor in the contribution of postprandial glucose to glycated haemoglobin (HbA1c) levels. Given the higher intake of carbohydrates and greater glycaemic responses to the same glycaemic load in Asians, it is likely that they may have different insulin requirements especially higher mealtime insulin doses. Overall, more well-designed studies should be conducted in different populations to elucidate how dietary carbohydrates could be targeted to optimize blood glucose regulation. Including low GI foods may benefit Asians who habitually consume higher refined carbohydrate cereal staple diets than Europeans.

2.5. Race/ethnic differences in determinants of insulin resistance and secretion

Ethnic differences have been consistently observed on the mean values of height, weight, body mass index (BMI), body composition, and fat distribution. In general, Africans have less visceral fat area but more skeletal muscle and bone mineral mass than Caucasians, even though they tend to have similar body sizes [7]. On the other hand, East Asians have smaller mean height, weight, BMI and less mean total visceral fat volume than Africans and Caucasians [48]. South Asians often present higher body fat and lower lean muscle mass at the same or lower BMIs compared with white people (the “high body fat-normal weight/BMI-low muscle mass” phenotype) [49].

Although Africans have less intra-abdominal visceral fat than Caucasians, it has been observed that they are more insulin resistant, have greater insulin secretion and lesser insulin clearance than white people [50]. In this scenario, the expected positive association between visceral fat and insulin resistance is not applied. Nevertheless, it is possible that the African’s large amount of muscle and bone mass affects insulin sensitivity determinants, potentially leading to insulin resistance and increased insulin response. A higher baseline insulin secretion or lower insulin clearance may be also necessary to keep and grow the great amount of muscle and bone in this population [7]. Additionally, it has been observed that Africans have lower ectopic and greater peripheral (gluteo-femoral) fat deposition than their European counterparts. This may indicate that either Africans are more sensitive to the effects of ectopic fat deposition or that ectopic fat is not an important mediator of T2DM in this population [50].

As addressed previously, healthy East Asians have a lower AIRg compared with Africans and Caucasians. It is likely that this may be a consequence of either 1) high insulin sensitivity due to low visceral fat content in healthy individuals or 2) lower baseline insulin secretion or higher insulin clearance sufficient to maintain a smaller body size compared with the other two groups. Furthermore, in the transition from NGT to IGT, insulin sensitivity may be markedly reduced,

while insulin response does not change significantly in East Asians. Nevertheless, insulin response may be rapidly reduced from IGT to T2DM [7].

It has been suggested that the pathogenesis of T2DM may differ in Asian populations compared with Caucasians. T2DM develops in Asian patients at a younger age and lower levels of BMI and waist circumference than white populations [51,52]. In fact, the BMI cutoff points for normal weight, overweight, and obesity were revised for Asians, and are now lower than the international classification criteria [53]. South Asians are disproportionately predisposed to diabetes. The underlying risk factors include higher insulin resistance, impaired β -cell function, an abnormal adipokine profile, and certain high risk genetic polymorphisms [34]. In the 1980s, Mohan et al. [54] observed that basal insulin levels and insulin response to a glucose load were higher in Asian Indians than Europeans. These results indicated that Asian Indians need higher levels of insulin to maintain euglycaemia and secrete higher amounts of insulin in response to the same glucose load [54]. Scholfield et al. [55] reported that Asian Indian vegetarians had significantly higher insulin levels than American vegetarians both in the fasting state and after an oral glucose load. Although they presented comparable diets, Asian Indians were more likely to be insulin resistant [55].

Given the same BMI, South Asians have higher total body fat and abdominal adipose tissue (both subcutaneous and visceral fat) than Caucasians [49]. This tendency to abdominal adiposity can result in increased fatty acid influx to the liver, impaired adipokine production, fatty liver, and hepatic insulin resistance [49,56]. Ectopic hepatic and intramyocellular fat deposition are important determinants of insulin resistance, which may propagate a vicious cycle with higher ectopic fat deposition in the liver and islets, hepatic insulin resistance, β -cell dysfunction and T2DM [49,57]. It has been

suggested that this predisposition to adiposity and insulin resistance begins during foetal development. Yajnik et al. [58] found that Indian babies were lighter and smaller than babies born in the U.K., but preserved body fat (the thin-fat Indian baby). This body composition might persist later in life, resulting in an insulin-resistant state [58].

Asians have shown a decreased insulin secretion capacity which further increases the risk of diabetes [7,32]. The underlying mechanisms are yet to be determined; however, it may be explained by lower β -cell mass, impaired β -cell function and/or genetic influences [32]. In the US, it was observed that non-diabetic adult South Asians and Chinese had the lowest insulin secretion, compared with Hispanics, African Americans, and whites [4]. In the pathogenesis of T2DM, it is usually described that high insulin resistance may trigger increased insulin production to maintain normoglycaemia, which can result in β -cell failure over the time. Nevertheless, in Asian Indians, β -cell dysfunction appears to be the primary aetiological factor in the development of T2DM [59]. Therefore, targeted interventions to preserve or improve beta cell function and specific pharmacological approaches may be necessary in this population.

2.6. Efficacy and safety of insulin therapy by race/ethnicity

Race/ethnicity poses a challenge for optimal treatment in T2DM patients. So far, most clinical trials have been conducted primarily among white individuals. The lack of racially/ethnically diverse participants in diabetes clinical trials raises concern for the efficacy and safety of a given insulin regimen in different populations [42].

In a post hoc analysis of pooled data from 11 multinational clinical trials involving 1455 patients with T2DM, the metabolic response to insulin therapy differed significantly across




Fig. 2 – Racial differences in achieving HbA1c level < 7% with ≥ 12 weeks of insulin therapy. Single asterisk indicates $p < .05$ and double asterisk $p < .01$ vs Caucasians. BASAL = insulin glargine or neutral protamine Hagedorn; LMBID = insulin lispro mix 75/25 twice daily; LMTID = insulin lispro mix 50/50 three times daily. Figure by Davidson et al. [42]. Non-commercial creative commons license.

ethnicities, depending on the insulin type and regimen intensity. Hispanics showed better glycaemic control than Caucasians with a 12- to 24-week regimen of basal therapy. Nevertheless, after 12 to 16 weeks of insulin lispro mix 75/25 twice daily, Hispanic, and Asian patients had poorer overall glycaemic control than Caucasians (Fig. 2). Furthermore, Asians experienced higher incidence and rate of severe hypoglycaemia than Caucasians with intensified premixed insulin therapy (insulin lispro mix 50/50 three times daily) [42]. In a retrospective case analysis of 280 T2DM patients treated for 12 months with insulin (regimen not specified), significantly greater HbA1c reductions were observed in African/Caribbean patients than in Caucasians or Asians, despite significantly smaller weight-adjusted insulin doses [60].

It has been reported that glycaemic control varies significantly by race/ethnicity. Despite controlling for factors affecting glycaemia, HbA1c levels are often significantly higher in non-Caucasians with T2DM, IGT or NGT. In a clinical trial involving 2094 patients from 11 countries, HbA1c was significantly higher in Hispanics, Asians, Africans, and patients of other racial/ethnic groups than Caucasians [61]. In a meta-analysis by Kirk et al. [62], African Americans and Hispanics had higher HbA1c values than NHW, independently of study design, data collection methodology, and type of medical care. The higher therapeutic failures in non-white populations [63] may suggest that ethnic-based insulin dosing and formulations are needed.

3. Conclusions

Until now, racial/ethnic-specific clinical practice recommendations are limited in international guidelines. Few studies have addressed outcome differences in glycaemic control related to race/ethnicity and specific insulin regimens.

It has been shown that treatment response to insulin therapy varies by race/ethnicity and warrants future large trials. Future prospective clinical trials should include subjects in their natural habitat (for instance, Africans in Africa, South Asians in South Asia, Chinese in China) and where they migrated to, as well as Europeans, South and Central Americans, etc. This kind of study should be conducted under International respected bodies, like IDF or in collaboration with the World Health Organization (WHO). The trials should be targeted to the efficacy and safety of different insulin regimens in diverse populations, considering their body and fat composition and specific food habits.

Given the high and increasing prevalence of T2DM particularly in non-white populations, more studies are needed to better understand the impact of race/ethnicity on the differential responses to insulin therapy. This may provide more personalized and targeted management strategies.

Definition of race/ethnic groups

South Asian: refers to Asian Indian, Pakistani, Sri Lankan, Bangladeshi, Nepali, Bhutanese, Afghan, and Maldivian. East Asian: refers to Japanese, Chinese, and Korean. Southeast Asian: refers to Filipino, Vietnamese, Cambodian, Laotian, Thai, Indonesian, Malaysian, Singaporean, and Hmong. His-

panic: refers to Puerto Rican, Cuban or Cuban American, Dominican (Republic), Mexican or Mexican American, Central or South American. Non-Hispanic Black (NHB): individuals of African descent or who self-identify as black or African American. Non-Hispanic Asian: non-Hispanic persons who do not self-identify as black and have origins in any of the Asian countries. Non-Hispanic White (NHW): non-Hispanic individuals not falling into the other categories who self-identify as white. Native American: refers to American Indians and Alaska Natives.

Funding

None.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

REFERENCE

- [1] Williams R, Karuranga S, Malanda B, Saeedi P, Basit A, Besançon S, et al. Global and regional estimates and projections of diabetes-related health expenditure: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. *Diabetes Res Clin Pract.* 2020 Feb 13:108072. doi: 10.1016/j.diabres.2020.108072.
- [2] Cheng YJ, Kanaya AM, Araneta MRG, Saydah SH, Kahn HS, Gregg EW, et al. Prevalence of Diabetes by Race and Ethnicity in the United States, 2011-2016. *JAMA.* 2019;322(24):2389-98. Epub 2019/12/21. doi: 10.1001/jama.2019.19365. PubMed PMID: 31860047; PubMed Central PMCID: PMC6990660.
- [3] Dagogo-Jack S. Ethnic disparities in type 2 diabetes: pathophysiology and implications for prevention and management. *J Natl Med Assoc.* 2003;95(9):774, 9-89. Epub 2003/10/07. PubMed PMID: 14527045; PubMed Central PMCID: PMC6990660.
- [4] Kanaya AM, Herrington D, Vittinghoff E, Ewing SK, Liu K, Blaha MJ, et al. Understanding the high prevalence of diabetes in U.S. south Asians compared with four racial/ethnic groups: the MASALA and MESA studies. *Diabetes Care.* 2014;37(6):1621-8. Epub 2014/04/08. doi: 10.2337/dc13-2656. PubMed PMID: 24705613; PubMed Central PMCID: PMC4030091.
- [5] Luhar S, Kondal D, Jones R, Anjana RM, Patel SA, Kinra S, et al. Lifetime risk of diabetes in metropolitan cities in India. *Diabetologia.* 2021;64(3):521-9. Epub 2020/11/24. doi: 10.1007/s00125-020-05330-1. PubMed PMID: 33225415; PubMed Central PMCID: PMC7864818.
- [6] Arroyo-Johnson C, Mincey KD, Ackermann N, Milam L, Goodman MS, Colditz GA. Racial and Ethnic Heterogeneity in Self-Reported Diabetes Prevalence Trends Across Hispanic Subgroups, National Health Interview Survey, 1997-2012. *Prev Chronic Dis.* 2016;13:E10. Epub 2016/01/23. doi: 10.5888/pcd13.150260. PubMed PMID: 26796518; PubMed Central PMCID: PMC472293
- [7] Kodama K, Tojjar D, Yamada S, Toda K, Patel CJ, Butte AJ. Ethnic differences in the relationship between insulin sensitivity and insulin response: a systematic review and meta-analysis. *Diabetes Care.* 2013;36(6):1789-96. Epub 2013/

- 05/25. doi: 10.2337/dc12-1235. PubMed PMID: 23704681; PubMed Central PMCID: PMCPMC3661854.
- [8] Lanting LC, Joung IM, Mackenbach JP, Lamberts SW, Bootsma AH. Ethnic differences in mortality, end-stage complications, and quality of care among diabetic patients: a review. *Diabetes Care*. 2005;28(9):2280- Epub 2005/08/27. doi: 10.2337/diacare.29.2280. PubMed PMID: 16123507.
- [9] Golden SH, Brown A, Cauley JA, Chin MH, Gary-Webb TL, Kim C, et al. Health disparities in endocrine disorders: biological, clinical, and nonclinical factors—an Endocrine Society scientific statement. *J Clin Endocrinol Metab*. 2012;97(9):E1579-63 Epub 2012/06/26. doi: 10.1210/jc.2012-2043. PubMed PMID: 22730516; PubMed Central PMCID: PMCPMC3431576.
- [10] Spanakis EK, Golden SH. Race/ethnic difference in diabetes and diabetic complications. *Curr Diab Rep*. 2013;13(6):814-23. Epub 2013/09/17. doi: 10.1007/s11892-013-0421-9. PubMed PMID: 24037313; PubMed Central PMCID: PMCPMC3830901.
- [11] Osei K, Schuster DP, Owusu SK, Amoah AG. Race and ethnicity determine serum insulin and C-peptide concentrations and hepatic insulin extraction and insulin clearance: comparative studies of three populations of West African ancestry and white Americans. *Metabolism*. 1997;46(1):53-8. Epub 1997/01/01. doi: 10.1016/s0026-0495(97)90167-0. PubMed PMID: 9005969.
- [12] Osei K, Gaillard T, Schuster DP. Pathogenetic mechanisms of impaired glucose tolerance and type II diabetes in African-Americans. The significance of insulin secretion, insulin sensitivity, and glucose effectiveness. *Diabetes Care*. 1997;20(3):396-404. Epub 1997/03/01. doi: 10.2337/diacare.20.3.396. PubMed PMID: 9051394.
- [13] Diaz VA, Mainous AG, 3rd, Koopman RJ, Geesey ME. Are ethnic differences in insulin sensitivity explained by variation in carbohydrate intake? *Diabetologia*. 2005;48(7):1264-8. Epub 2005/05/03. doi: 10.1007/s00125-005-1745-z. PubMed PMID: 15864537.
- [14] Vecchio I, Tornali C, Bragazzi NL, Martini M. The Discovery of Insulin: An Important Milestone in the History of Medicine. *Front Endocrinol (Lausanne)*. 2018;9:613. Epub 2018/11/09. doi: 10.3389/fendo.2018.00613. PubMed PMID: 30405529; PubMed Central PMCID: PMCPMC6205949.
- [15] Fralick M, Zinman B. The discovery of insulin in Toronto: beginning a 100 year journey of research and clinical achievement. *Diabetologia*. 2021;64(5):947-53. Epub 2021/01/26. doi: 10.1007/s00125-020-05371-6. PubMed PMID: 33492422.
- [16] American Diabetes A. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2021. *Diabetes Care*. 2021;44(Suppl 1):S111-S24. Epub 2020/12/11. doi: 10.2337/dc21-S009. PubMed PMID: 33298420.
- [17] Bliss M. *The discovery of insulin*. Chicago: The University of Chicago Press; 1984.
- [18] Skyler JS, Seigler DE, Reeves ML. Optimizing pumped insulin delivery. *Diabetes Care*. 1982;5(2):135-9. Epub 1982/03/01. doi: 10.2337/diacare.5.2.135. PubMed PMID: 6927721.
- [19] Davidson PC, Hebblewhite HR, Steed RD, Bode BW. Analysis of guidelines for basal-bolus insulin dosing: basal insulin, correction factor, and carbohydrate-to-insulin ratio. *Endocr Pract*. 2008;14(9):1095-101. Epub 2009/01/23. doi: 10.4158/EP.14.9.1095. PubMed PMID: 19158048.
- [20] Walsh J, Roberts R, Bailey T. Guidelines for insulin dosing in continuous subcutaneous insulin infusion using new formulas from a retrospective study of individuals with optimal glucose levels. *J Diabetes Sci Technol*. 2010;4(5):1174-81. Epub 2010/10/06. doi: 10.1177/193229681000400516. PubMed PMID: 20920437; PubMed Central PMCID: PMCPMC2956816.
- [21] King AB, Kuroda A, Matsuhisa M, Hobbs T. A Review of Insulin-Dosing Formulas for Continuous Subcutaneous Insulin Infusion (CSII) for Adults with Type 1 Diabetes. *Curr Diab Rep*. 2016;16(9):83. Epub 2016/07/28. doi: 10.1007/s11892-016-0772-0. PubMed PMID: 27457238; PubMed Central PMCID: PMCPMC4960276.
- [22] Grunberger G, Abelseh JM, Bailey TS, Bode BW, Handelsman Y, Hellman R, et al. Consensus Statement by the American Association of Clinical Endocrinologists/American College of Endocrinology insulin pump management task force. *Endocr Pract*. 2014;20(5):463-89. Epub 2014/05/13. doi: 10.4158/EP14145.PS. PubMed PMID: 24816754.
- [23] King AB. Reassessment of insulin dosing guidelines in continuous subcutaneous insulin infusion treated type 1 diabetes. *Curr Diab Rep*. 2014;14(6):503. Epub 2014/05/06. doi: 10.1007/s11892-014-0503-3. PubMed PMID: 24792068.
- [24] Bisschop PH, de Metz J, Ackermans MT, Endert E, Pijl H, Kuipers F, et al. Dietary fat content alters insulin-mediated glucose metabolism in healthy men. *Am J Clin Nutr*. 2001;73(3):554-9. Epub 2001/03/10. doi: 10.1093/ajcn/73.3.554. PubMed PMID: 11237931.
- [25] Sowmya N, Lakshmi N, Arumugam K, Venkatachalam S, Vijayalakshmi P, Ruchi V, et al. Comparison of dietary profile of a rural south Indian population with the current dietary recommendations for prevention of non-communicable diseases (CURES 147). *Indian J Med Res*. 2016;144(1):112-9. Epub 2016/11/12. doi: 10.4103/0971-5916.193297. PubMed PMID: 27834334; PubMed Central PMCID: PMCPMC5116883.
- [26] Kahn SE, Prigeon RL, McCulloch DK, Boyko EJ, Bergman RN, Schwartz MW, et al. Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function. *Diabetes*. 1993;42(11):1663-72. Epub 1993/11/01. doi: 10.2337/diab.42.11.1663. PubMed PMID: 8405710.
- [27] Gibson G. Decanalization and the origin of complex disease. *Nat Rev Genet*. 2009;10(2):134-40. Epub 2009/01/03. doi: 10.1038/nrg2502. PubMed PMID: 19119265.
- [28] Haffner SM. Epidemiology of type 2 diabetes: risk factors. *Diabetes Care*. 1998;21 Suppl 3:C3-6. Epub 1998/12/16. doi: 10.2337/diacare.21.3.c3. PubMed PMID: 9850478.
- [29] Fujimoto WY. *Overview of non-insulin-dependent diabetes mellitus (NIDDM) in different population groups*. *Diabet Med* 1996;13(9 Suppl 6):S7-10. Epub 1996/09/01 PubMed PMID: 8894472.
- [30] Hu FB. Globalization of diabetes: the role of diet, lifestyle, and genes. *Diabetes Care*. 2011;34(6):1249-57. Epub 2011/05/28. doi: 10.2337/dc11-0442. PubMed PMID: 21617109; PubMed Central PMCID: PMCPMC3114340.
- [31] Hales CN, Barker DJ. Type 2 (non-insulin-dependent) diabetes mellitus: the thrifty phenotype hypothesis. *Diabetologia*. 1992;35(7):595-601. Epub 1992/07/01. doi: 10.1007/BF00400248. PubMed PMID: 1644236.
- [32] Narayan KMV, Kanaya AM. Why are South Asians prone to type 2 diabetes? A hypothesis based on underexplored pathways. *Diabetologia*. 2020;63(6):1103-9. Epub 2020/04/03. doi: 10.1007/s00125-020-05132-5. PubMed PMID: 32236731; PubMed Central PMCID: PMCPMC75311
- [33] Bavdekar A, Yajnik CS, Fall CH, Bapat S, Pandit AN, Deshpande V, et al. Insulin resistance syndrome in 8-year-old Indian children: small at birth, big at 8 years, or both? *Diabetes*. 1999;48(12):2422-9. Epub 1999/12/02. doi: 10.2337/diabetes.48.12.2422. PubMed PMID: 10580432.
- [34] Shah A, Kanaya AM. Diabetes and associated complications in the South Asian population. *Curr Cardiol Rep*. 2014;16(5):476. Epub 2014/03/20. doi: 10.1007/s11886-014-0476-5. PubMed PMID: 24643902; PubMed Central PMCID: PMCPMC4026332.
- [35] Ravelli AC, van der Meulen JH, Michels RP, Osmond C, Barker DJ, Hales CN, et al. Glucose tolerance in adults after prenatal exposure to famine. *Lancet*. 1998;351(9097):173-7. Epub 1998/

- 02/05. doi: 10.1016/s0140-6736(97)07244-9. PubMed PMID: 9449872.
- [36] de Rooij SR, Painter RC, Phillips DI, Osmond C, Michels RP, Godsland IF, et al. Impaired insulin secretion after prenatal exposure to the Dutch famine. *Diabetes Care*. 2006;29(8):1897-901. Epub 2006/07/29. doi: 10.2337/dc06-0460. PubMed PMID: 16873799.
- [37] Lumey LH, Khalangot MD, Vaiserman AM. Association between type 2 diabetes and prenatal exposure to the Ukraine famine of 1932-33: a retrospective cohort study. *Lancet Diabetes Endocrinol*. 2015;3(10):787-94. Epub 2015/09/08. doi: 10.1016/S2213-8587(15)00279-X. PubMed PMID: 26342852.
- [38] King H, Keuky L, Seng S, Khun T, Roglic G, Pinget M. Diabetes and associated disorders in Cambodia: two epidemiological surveys. *Lancet*. 2005;366(9497):1633-9. Epub 2005/11/08. doi: 10.1016/S0140-6736(05)67662-3. PubMed PMID: 16271644.
- [39] Zimmet P, Shi Z, El-Osta A, Ji L. Epidemic T2DM, early development and epigenetics: implications of the Chinese Famine. *Nat Rev Endocrinol*. 2018;14(12):738-46. Epub 2018/10/13. doi: 10.1038/s41574-018-0106-1. PubMed PMID: 30310152.
- [40] Henry CJ, Quek RYC, Kaur B, Shyam S, Singh HKG. A glycaemic index compendium of non-western foods. *Nutr Diabetes*. 2021;11(1):2. Epub 2021/01/09. doi: 10.1038/s41387-020-00145-w. PubMed PMID: 33414403; PubMed Central PMCID: PMCPCMC7791047.
- [41] Venn BS, Williams SM, Mann JI. Comparison of postprandial glycaemia in Asians and Caucasians. *Diabet Med*. 2010;27(10):1205-8. Epub 2010/09/30. doi: 10.1111/j.1464-5491.2010.03069.x. PubMed PMID: 20873364.
- [42] Davidson JA, Lacaya LB, Jiang H, Heilmann CR, Scism-Bacon JL, Gates JR, et al. Impact of race/ethnicity on the efficacy and safety of commonly used insulin regimens: a post hoc analysis of clinical trials in type 2 diabetes mellitus. *Endocr Pract*. 2010;16(5):818-28. Epub 2010/05/05. doi: 10.4158/EP09285.OR. PubMed PMID: 20439249.
- [43] Dickinson S, Colagiuri S, Faramus E, Petocz P, Brand-Miller JC. Postprandial hyperglycemia and insulin sensitivity differ among lean young adults of different ethnicities. *J Nutr*. 2002;132(9):2574-9. Epub 2002/09/11. doi: 10.1093/jn/132.9.2574. PubMed PMID: 12221211.
- [44] Hsu WC, Lau KH, Matsumoto M, Moghazy D, Keenan H, King GL. Improvement of insulin sensitivity by isoenergy high carbohydrate traditional Asian diet: a randomized controlled pilot feasibility study. *PLoS One*. 2014;9(9):e106851. Epub 2014/09/17. doi: 10.1371/journal.pone.0106851. PubMed PMID: 25226279; PubMed Central PMCID: PMCPCMC4167335.
- [45] Camps SG, Kaur B, Quek RYC, Henry CJ. Does the ingestion of a 24 hour low glycaemic index Asian mixed meal diet improve glycaemic response and promote fat oxidation? A controlled, randomized cross-over study. *Nutr J*. 2017;16(1):43. Epub 2017/07/14. doi: 10.1186/s12937-017-0258-1. PubMed PMID: 28701162; PubMed Central PMCID: PMCPCMC5508658.
- [46] Bhavadharini B, Mohan V, Dehghan M, Rangarajan S, Swaminathan S, Rosengren A, et al. White Rice Intake and Incident Diabetes: A Study of 132,373 Participants in 21 Countries. *Diabetes Care*. 2020;43(11):2643-50. Epub 2020/09/03. doi: 10.2337/dc19-2335. PubMed PMID: 32873587; PubMed Central PMCID: PMCPCMC7576435.
- [47] Kataoka M, Venn BJ, Williams SM, Te Morenga LA, Heemels IM, Mann JI. Glycaemic responses to glucose and rice in people of Chinese and European ethnicity. *Diabet Med*. 2013;30(3):e101-7. Epub 2012/11/28. doi: 10.1111/dme.12080. PubMed PMID: 23181689.
- [48] Tanaka S, Horimai C, F K. Ethnic differences in abdominal visceral fat accumulation between Japanese, African-Americans, and Caucasians: a meta-analysis. *Acta Diabetol* 2003;40:S302-S4.
- [49] Misra A, Jayawardena R, Anoop S. Obesity in South Asia: Phenotype, Morbidities, and Mitigation. *Curr Obes Rep*. 2019;8(1):43-52. Epub 2019/02/08. doi: 10.1007/s13679-019-0328-0. PubMed PMID: 30729382.
- [50] Goedecke JH, Olsson T. Pathogenesis of type 2 diabetes risk in black Africans: a South African perspective. *J Intern Med*. 2020;288(3):284-94. Epub 2020/04/18. doi: 10.1111/joim.13083. PubMed PMID: 32303113.
- [51] Ma RC, Chan JC. Type 2 diabetes in East Asians: similarities and differences with populations in Europe and the United States. *Ann N Y Acad Sci*. 2013;1281:64-91. Epub 2013/04/05. doi: 10.1111/nyas.12098. PubMed PMID: 23551121; PubMed Central PMCID: PMCPCMC3708105.
- [52] Gujral UP, Pradeepa R, Weber MB, Narayan KM, Mohan V. Type 2 diabetes in South Asians: similarities and differences with white Caucasian and other populations. *Ann N Y Acad Sci*. 2013;1281:51-63. Epub 2013/01/16. doi: 10.1111/j.1749-6632.2012.06838.x. PubMed PMID: 23317344; PubMed Central PMCID: PMCPCMC3715105.
- [53] Choo V. WHO reassesses appropriate body-mass index for Asian populations. *Lancet*. 2002;360(9328):235. Epub 2002/07/23. doi: 10.1016/S0140-6736(02)09512-0. PubMed PMID: 12133671.
- [54] Mohan V, Sharp PS, Cloke HR, Burrin JM, Schumer B, Kohner EM. Serum immunoreactive insulin responses to a glucose load in Asian Indian and European type 2 (non-insulin-dependent) diabetic patients and control subjects. *Diabetologia*. 1986;29(4):235-7. Epub 1986/04/01. doi: 10.1007/BF00454882. PubMed PMID: 3519338.
- [55] Scholfield DJ, Behall KM, Bhatena SJ, Kelsay J, Reiser S, Revett KR. A study on Asian Indian and American vegetarians: indications of a racial predisposition to glucose intolerance. *Am J Clin Nutr*. 1987;46(6):955-61. Epub 1987/12/01. doi: 10.1093/ajcn/46.6.955. PubMed PMID: 3318380.
- [56] Sniderman AD, Bhopal R, Prabhakaran D, Sarrafzadegan N, Tchernof A. Why might South Asians be so susceptible to central obesity and its atherogenic consequences? The adipose tissue overflow hypothesis. *Int J Epidemiol*. 2007;36(1):220-5. Epub 2007/05/19. doi: 10.1093/ije/dyl245. PubMed PMID: 17510078.
- [57] Taylor R. Pathogenesis of type 2 diabetes: tracing the reverse route from cure to cause. *Diabetologia*. 2008;51(10):1781-9. Epub 2008/08/30. doi: 10.1007/s00125-008-1116-7. PubMed PMID: 18726585.
- [58] Yajnik CS, Fall CH, Coyaji KJ, Hirve SS, Rao S, Barker DJ, et al. Neonatal anthropometry: the thin-fat Indian baby. The Pune Maternal Nutrition Study. *Int J Obes Relat Metab Disord*. 2003;27(2):173-80. Epub 2003/02/15. doi: 10.1038/sj.ijo.802219. PubMed PMID: 12586996.
- [59] Staimez LR, Weber MB, Ranjani H, Ali MK, Echouffo-Tcheugui JB, Phillips LS, et al. Evidence of reduced beta-cell function in Asian Indians with mild dysglycemia. *Diabetes Care*. 2013;36(9):2772-8. Epub 2013/04/19. doi: 10.2337/dc12-2290. PubMed PMID: 23596180; PubMed Central PMCID: PMCPCMC3747932.
- [60] Karalliedde J, Smith A, Viberti G. Determinants of response to insulin therapy following failure of oral agents in type 2 diabetes. *Diabetes Care*. 2005;28(10):2589-90. Epub 2005/09/28. doi: 10.2337/diacare.28.10.2589. PubMed PMID: 16186308.
- [61] Herman WH, Dungan KM, Wolffenbuttel BH, Buse JB, Fahrback JL, Jiang H, et al. Racial and ethnic differences in mean plasma glucose, hemoglobin A1c, and 1,5-anhydroglucitol in over 2000 patients with type 2 diabetes. *J Clin Endocrinol Metab*. 2009;94(5):1689-94. Epub 2009/03/12. doi: 10.1210/jc.2008-1940. PubMed PMID: 19276235.

-
- [62] Kirk JK, Passmore LV, Bell RA, Narayan KM, D'Agostino RB, Jr., Arcury TA, et al. Disparities in A1C levels between Hispanic and non-Hispanic white adults with diabetes: a meta-analysis. *Diabetes Care*. 2008;31(2):240-6. Epub 2007/11/06. doi: 10.2337/dc07-0382. PubMed PMID: 17977939.
- [63] Bonds DE, Zaccaro DJ, Karter AJ, Selby JV, Saad M, Goff DC, Jr. Ethnic and racial differences in diabetes care: The Insulin Resistance Atherosclerosis Study. *Diabetes Care*. 2003;26(4):1040-6. Epub 2003/03/29. doi: 10.2337/diacare.26.4.1040. PubMed PMID: 12663570.